QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
NASDAQ:AGTC

Applied Genetic Technologies - AGTC Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.39
▼
$0.39
50-Day Range
$0.37
▼
$0.42
52-Week Range
$0.23
▼
$2.83
Volume
N/A
Average Volume
943,490 shs
Market Capitalization
$26.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Applied Genetic Technologies MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
1,763.1% Upside
$7.33 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.92) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.47 out of 5 stars

Medical Sector

968th out of 1,048 stocks

Biological Products, Except Diagnostic Industry

158th out of 168 stocks

See Top Rated MarketRank™ Stocks Here

AGTC stock logo

About Applied Genetic Technologies (NASDAQ:AGTC) Stock

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Stock News Headlines

January 5, 2023 | thestreet.com
Applied Genetic Technologies (AGTC) Stock Climbs on $124 Million Biogen Deal
November 28, 2022 | finance.yahoo.com
*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*
January 26, 2023 | Investing Trends (Ad)
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
November 22, 2022 | finance.yahoo.com
*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*
November 15, 2022 | finance.yahoo.com
Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022
November 3, 2022 | finance.yahoo.com
Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022
October 25, 2022 | finance.yahoo.com
Florida investment firm looks to take Cambridge gene therapy startup private
October 24, 2022 | lse.co.uk
Syncona to acquire retinal therapy firm Applied Genetic Technologies
January 26, 2023 | PressReach (Ad)
Stocks News Announcement
Don't miss this update. Read the press release about Small Pharma.
October 23, 2022 | finance.yahoo.com
Syncona to Acquire Applied Genetic Technologies Corporation
October 18, 2022 | markets.businessinsider.com
iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis
September 30, 2022 | msn.com
HC Wainwright & Co. Maintains Buy Rating for Applied Genetic: Here's What You Need To Know
September 23, 2022 | fool.com
Applied Genetic Technologies (NASDAQ: AGTC)
August 29, 2022 | reuters.com
Applied Genetic Technologies Corp
July 26, 2022 | finance.yahoo.com
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
July 13, 2022 | finance.yahoo.com
AGTC Announces Pricing of $10 Million Underwritten Public Offering
July 12, 2022 | finance.yahoo.com
AGTC Announces Proposed Underwritten Public Offering
June 8, 2022 | finance.yahoo.com
AGTC Announces Key Appointments to Leadership Team
June 6, 2022 | finance.yahoo.com
AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
May 18, 2022 | finance.yahoo.com
AGTC to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022 | finance.yahoo.com
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
May 10, 2022 | finance.yahoo.com
AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion
May 4, 2022 | finance.yahoo.com
Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
May 2, 2022 | tmcnet.com
AGTC to Present Preclinical Research Supporting Gene Therapy
May 2, 2022 | finance.yahoo.com
AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy
April 14, 2022 | finance.yahoo.com
AGTC to Present at Cell & Gene Meeting on the Mediterranean
March 22, 2022 | finance.yahoo.com
AGTC Announces Pricing of Public Offering of Common Stock
See More Headlines

Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Company Calendar

Last Earnings
11/09/2021
Today
1/26/2023
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
6/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGTC
CUSIP
N/A
CIK
1273636
Web
www.agtc.com
Phone
(386) 462-2204
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+662.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,940,000.00
Net Margins
N/A
Pretax Margin
-21,537.54%
Return on Equity
-192.90%
Return on Assets
-92.54%

Debt

Debt-to-Equity Ratio
0.39
Current Ratio
1.40
Quick Ratio
1.40

Sales & Book Value

Annual Sales
$320,000.00
Price / Sales
83.19
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.26 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
67,632,000
Free Float
64,859,000
Market Cap
$26.62 million
Optionable
Optionable
Beta
1.55

Key Executives

  • Ms. Susan B. WasherMs. Susan B. Washer (Age 61)
    Pres, CEO & Director
    Comp: $747.84k
  • Mr. Jonathan I. Lieber M.B.A. (Age 52)
    Chief Financial Officer
    Comp: $533.14k
  • Dr. Susan Schneider M.D. (Age 64)
    Chief Medical Officer
    Comp: $480.32k
  • Dr. Nicholas Muzyczka
    Co-Founder
  • Dr. Barry J. Byrne M.D.
    Ph.D., Co-Founder
  • Dr. William W. Hauswirth
    Co-Founder & Member of Ophthalmology Scientific Advisory Board
  • Dr. Richard Jude Samulski Ph.D.
    Co-Founder
  • Dr. Terence R. Flotte M.D.
    Co-Founder
  • Mr. Gerald Anthony Reynolds
    Chief Accounting Officer, Principal Accounting Officer & Treasurer
  • Dr. Abraham Scaria Ph.D. (Age 63)
    Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AGTC Stock - Frequently Asked Questions

Should I buy or sell Applied Genetic Technologies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGTC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGTC, but not buy additional shares or sell existing shares.
View AGTC analyst ratings or view top-rated stocks.

What is Applied Genetic Technologies' stock price forecast for 2023?

8 equities research analysts have issued 12-month price objectives for Applied Genetic Technologies' shares. Their AGTC share price forecasts range from $3.00 to $16.00. On average, they expect the company's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 1,763.1% from the stock's current price.
View analysts price targets for AGTC or view top-rated stocks among Wall Street analysts.

When is Applied Genetic Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our AGTC earnings forecast.

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same period in the prior year, the company posted ($0.60) EPS.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $0.39.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies (NASDAQ:AGTC) has a market capitalization of $26.62 million and generates $320,000.00 in revenue each year. The biotechnology company earns $-68,940,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The official website for the company is www.agtc.com. The biotechnology company can be reached via phone at (386) 462-2204 or via email at david.carey@finnpartners.com.

This page (NASDAQ:AGTC) was last updated on 1/26/2023 by MarketBeat.com Staff